Adlai Nortye Group (ANL) vs Jade Biosciences (JBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Jade Biosciences (JBIO) over the past year, gaining 712.1% versus a gain of 52.3%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $899.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | JBIO |
|---|---|---|
| Share price | $15.51 | $14.15 |
| Market cap | $998.81M | $899.90M |
| 1-day change | +10.39% | +2.76% |
| YTD return | +889.44% | -10.76% |
| 1-year return | +712.14% | +52.32% |
| 5-year return | — | -97.22% |
| EPS (TTM) | $-0.66 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $28.00 |
| 52-week low | $0.879 | $8.36 |
| Distance from 52-week high | -10.09% | -49.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.20% | +254.28% |
| Average volume | 175.26K | 888.66K |
| Shares outstanding | 58.73M | 63.60M |
| Employees | 109 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed JBIO by 659.8 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
ANL vs JBIO FAQ
Which is bigger, Adlai Nortye Group or Jade Biosciences?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $899.90M for Jade Biosciences (JBIO).
Which stock has performed better over the past year, ANL or JBIO?
ANL returned +712.14% over the past 12 months, compared with +52.32% for JBIO (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Jade Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.